The Impact of Sampling Type, Frequency and Scale of Collection System on SARS-CoV-2 Quantification Fidelity

Abstract

With the rapid onset of the COVID-19 pandemic, wastewater-based epidemiology (WBE) sampling methodologies for SARS-CoV-2 were often implemented quickly and may not have taken the unique drainage catchment characteristics into account. One question of debate is the relevance of grab versus composite samples when surveying for SARS-CoV-2 at various catchment scales. This study assessed the impact of grab versus composite sampling on the detection and quantification of SARS-CoV-2 in catchment basins with flow rates ranging from high-flow (wastewater treatment plant influent), to medium-flow (neighborhood-scale micro-sewershed), to low-flow (city block-scale micro-sewershed) and down to ultra-low flow (building scale). At the high-flow site, grab samples were reasonably comparable to 24-h composite samples with the same non-detect rate (0%) and SARS-CoV-2 concentrations that differed by 32% on the Log₁₀ scale. However, as the flow rates decreased, the percentage of false-negative grab samples increased up to 44% and the SARS-CoV-2 concentrations of grab samples varied by up to 1-2 orders of magnitude compared to their respective composite sample concentrations. At the ultra-low-flow site, increased sampling frequencies down to every 5 min led to composite samples with higher fidelity to the SARS-CoV-2 load. Thus, composite sampling is superior to grab sampling, especially as flow decreases.

Synopsis The need for composite sampling to generate reliable SARS-CoV-2 wastewater based epidemiology results increases as the collection basin scale decreases.

• Download figure
• Open in new tab

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the National Science Foundation RAPID #2027679. Clean Water Services participated in this research with partial funding from the CARES Act through the Washington County Cities and Special District Assistance program.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Oregon State University's IRB has given this work an exemption.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes